Managing Superficial Bladder Cancer with Intravesical Therapy
Author Information
Author(s): D. Newling
Primary Institution: Princess Royal Hospital
Hypothesis
The high recurrence rate of superficial transitional cell carcinoma can be reduced through the application of topical intravesical therapy.
Conclusion
Intravesical therapy using agents like thiotepa and BCG is effective in preventing the recurrence of superficial bladder tumors.
Supporting Evidence
- Thiotepa was found to be more effective than VM26 and TUR alone in preventing recurrence.
- BCG and mitomycin C were equally effective in preventing recurrence of superficial bladder tumors.
- Patients receiving intravesical chemotherapy had a much lower rate of recurrence compared to those who only had TUR.
Takeaway
Doctors can use special treatments directly in the bladder to help stop bladder cancer from coming back after surgery.
Methodology
The EORTC GU Group conducted a series of studies comparing different intravesical therapies for superficial bladder cancer.
Limitations
The studies were complex and slow to recruit patients, and some had ethical concerns.
Participant Demographics
Patients with superficial bladder tumors, including those with recurrent tumors.
Want to read the original?
Access the complete publication on the publisher's website